Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy.
暂无分享，去创建一个
Jae-Weon Kim | V. Gebski | A. Oza | J. Ledermann | T. Park-Simon | I. Vergote | M. Friedlander | N. Colombo | G. Sonke | S. Lord | T. Huzarski | R. Penson | E. Pujade-Lauraine | L. Gladieff | Jung-Yun Lee | K. Fujiwara | C. Pisano | R. Asher | J. Korach | S. I. Kim | L. Manso | A. Tjokrowidjaja | C. Lee